about
Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosisUpregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis.Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disordersThe association between cancer and amyotrophic lateral sclerosis.AMPA receptors as drug targets in neurological disease--advantages, caveats, and future outlook.Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.Immune system alterations in amyotrophic lateral sclerosis.Moving forward in clinical trials for ALS: motor neurons lead the way please.Pathogenic role of ganglioside metabolism in neurodegenerative diseases.Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders.Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(®) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis.Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement.Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients.A voice-sensitive microswitch for a man with amyotrophic lateral sclerosis and pervasive motor impairment.A man with amyotrophic lateral sclerosis uses a mouth pressure microswitch to operate a text messaging system with a word prediction function.
P2860
Q28481242-B4EE4553-0B2F-4E00-A66C-B55A145FD34AQ33746277-7C479C97-A61A-4398-9101-5DCFBEF488E2Q36166654-4714272D-59CD-4698-A9B9-C996743C565DQ36487523-AB8D6EBB-9C3C-4CAC-9C31-C24382FE8E58Q38019570-3E897A3B-A0EE-4422-997D-C0C2F33D175FQ38022265-FE87EC85-AA06-478C-862E-1AE666D0439EQ38095543-69A14A08-AA46-44E7-8DD9-94C8E5D0C361Q38156505-506E9E60-F7EE-4F23-9F9E-F95921BA1B01Q38218040-7731BD54-026E-4F7F-B964-5341B1CDF26AQ38395012-B098CD14-2FEF-4992-A472-819C7EDD3242Q38563981-6C09DF7E-17CF-4789-AFA9-6160E8DB411BQ39215660-19579FC3-3AF8-47E7-8A93-1619C151E393Q42369773-ABE5A97C-718F-40A4-9298-6738CC6FC1DEQ48242279-4EF91A19-E6E3-4FB8-92AB-0370558DC967Q48258718-3883398F-00E9-4F59-A288-C755451C491EQ50473275-A95971CA-1274-4B9B-A0B1-E371EA5BEE74
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Emerging drugs for amyotrophic lateral sclerosis.
@en
Emerging drugs for amyotrophic lateral sclerosis.
@nl
type
label
Emerging drugs for amyotrophic lateral sclerosis.
@en
Emerging drugs for amyotrophic lateral sclerosis.
@nl
prefLabel
Emerging drugs for amyotrophic lateral sclerosis.
@en
Emerging drugs for amyotrophic lateral sclerosis.
@nl
P2860
P1476
Emerging drugs for amyotrophic lateral sclerosis.
@en
P2093
Ali Aamer Habib
P2860
P304
P356
10.1517/14728214.2011.604312
P407
P577
2011-08-01T00:00:00Z